Non-Hodgkin Lymphoma (NHL)

Latest News

Cleveland Clinic Main Campus | Image: Cleveland Clinic

Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

By Laura Joszt, MA

June 19th 2025

Coverage from IVBM Cleveland, held May 15, 2025.

large B-cell lymphoma | Image credit: Cleveland Clinic

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

By Mary Caffrey

June 17th 2025

Follicular lymphoma | Image: The Follicular Lymphoma Foundation

A Look at Those With Durable Responses to Epcoritamab in LBCL

By Mary Caffrey

June 14th 2025

Ian W. Flinn, MD, PhD | Image credit: OneOncology

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

By Mary Caffrey

June 10th 2025

The findings show that ctDNA is worthy of additional study as a tool for assessing risk and treatment response in large B-cell lymphoma, the authors concluded. | Image credit: Connect world - stock.adobe.com

Biomarker-Adapted Treatment Effective in High-Risk LBCL

By Jared Kaltwasser

June 7th 2025

Continuing Medical Education

View All

June 21st 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

June 21st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 21st 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

June 21st 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

June 21st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

June 21st 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Symbol of pancreatic cancer. Purple awareness ribbon: © Vitalii Vodolazskyi - stock.adobe.com

July 18th 2023

In Pancreatic DLBCL, Older Age, Distant Stage, Lack of Surgery Lead to Worse Outcomes

Jared Kaltwasser

Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.

Colorful cell interaction - tumor cell surrounded with immune cells (Generative AI): © Nevio - stock.adobe.com

July 11th 2023

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

Gianna Melillo

These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.

PET/CT is a nuclear medicine device that uses a combination of PET (Positron Emission Tomography) and Computed Tomography technology to diagnose cancer. Brain and nervous system myocardial ischemia: © workphoto - stock.adobe.com

July 8th 2023

Complicated Case of DLBCL Shows Limits of 18F-FDG PET/CT Imaging

Jared Kaltwasser

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

White blood cells in leukemia, AI Generative: © Катерина Євтехова - stock.adobe.com

July 5th 2023

Evolutionary Dynamics Drive Behind Outcomes in Late DLBCL Relapses

Jared Kaltwasser

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

June 28th 2023

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

Mary Caffrey

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

Finding solutions to complex cases from several perspectives. High angle shot of a group of medical practitioners having a discussion together in a hospital: © Kirsten D/peopleimages.com - stock.adobe.com

June 27th 2023

Patient Complaining of Abdominal Pain Found to Have Unusual Case of DLBCL

Jared Kaltwasser

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

June 9th 2023

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

Mary Caffrey Rose McNulty

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

depressed older man sitting with his head in his hand

June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA

Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.

June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

May 19th 2023

Epcoritamab Approved by FDA to Treat R/R DLBCL

Mary Caffrey

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

February 4th 2023

ASH 2022: Bispecific Antibodies

Mary Caffrey Hayden E. Klein

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

December 29th 2022

Top 5 Clinical Spotlight Interviews of 2022

AJMC Staff

Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.

<1 2 3 4 5 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions